Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH MDS 2021 | Immunological impact of TP53 in MDS

Shahram Kordasti • 27 Jan 2021
ESH MDS 2021
Myelodysplastic Syndromes

Shahram Kordasti, MD, PhD, King’s College London, London, UK, discusses the immunological effects of TP53 mutations in myelodysplastic syndromes (MDS) and how these impact prognosis. This interview took place during the 2021 European School of Hematology (ESH) 7th Translational Research E-Conference on Myelodysplastic Syndromes.

More from Shahram Kordasti

2:06
Understanding the role of inflammation and the immunome in MDS pathophysiology
Shahram Kordasti • 5 Apr 2024
2:53
Immune checkpoint inhibitors in MDS: the i4MDS consortium
Shahram Kordasti • 5 Apr 2024
4:27
The role of immune checkpoint inhibitors in MDS
Shahram Kordasti • 22 Sep 2021
6:05
The immune system's role in higher-risk MDS
Shahram Kordasti • 22 Sep 2021

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
3:19
Key clinical trials in MDS taking place in the US
Guillermo Garcia-Manero • 9 Apr 2024
1:34
Sequencing of agents in LR-MDS
Guillermo Garcia-Manero • 9 Apr 2024
1:21
HMAs for MDS- a party of one
Guillermo Garcia-Manero • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals